Belladonna and Opium Suppositories CII
Generic Name and Formulations:
Belladonna extract (powdered), opium (powdered); 16.2mg/30mg, 16.2mg/60mg.
Indications for Belladonna and Opium Suppositories:
Moderate to severe pain associated with ureteral spasms.
1 supp rectally once or twice daily; max 4 doses/day.
Glaucoma. Severe hepatic or renal disease. Asthma. Narcotic idiosyncrasies. Respiratory depression. Convulsive disorders. Acute alcoholism. Delirium tremens. Premature labor.
Idiosyncrasies to atropine and related drugs. Cardiac disease. Incipient glaucoma. GI or GU obstruction. Increased intracranial pressure. Toxic psychosis. Myxedema. Drug abusers. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers.
CNS effects potentiated with alcohol, other CNS depressants, MAOIs, tricyclic antidepressants, anticholinergics. Potentiated by anticholinergics.
Antispasmodic + opioid.
Drowsiness, anticholinergic effects (eg, dry mouth, urinary retention, dizziness, blurred vision, constipation), photophobia, tachycardia, GI upset, pruritus, urticaria.
Formerly known under the brand name B&O Supprettes 15A, B&O Supprettes 16A.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|